A two-drug combination exhibited durable clinical benefit as second- or third-line treatment for pancreatic cancer, according to a topline data announcement released by one of the agent’s ...
TheStreet on MSN
Molecule to medicine: How Daraxonrasib is rewriting pancreatic cancer drug development
Monash University's Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median ...
A new pancreatic cancer treatment may finally move the needle on what's proved to be an unforgiving disease. Fred Hutch ...
Treeline Biosciences, a well-funded cancer company that has raised more than $1 billion since its 2021 founding, is looking ...
We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. Revolution Medicines (NASDAQ ...
Shares of Tango Therapeutics gained after the company reported positive initial data from an ongoing study of a potential treatment for pancreatic cancer. The stock climbed 45% to $29.24 in premarket ...
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month ...
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet ...
An expert highlights phase 3 trial data evaluating darovasertib as targeted therapy for advanced metastatic pancreatic ...
Finerenone also reduced albuminuria at month 12 by 42% and lowered the risk of kidney failure or an eGFR decline of 40% or ...
Kasi: The overall response rate and the reported side effects don’t necessarily encompass the tangible impact that we're ...
New research presented at the 63rd ERA Congress suggests that a widely used class of blood pressure medications may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results